Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.

Agnes Mattsson,Sandra Eketorp Sylvan,Per Axelsson,Fredrik Ellin,Christian Kjellander,Karin Larsson,Birgitta Lauri,Catharina Lewerin,Christian Scharenberg,Love Tätting,Hemming Johansson,Anders Österborg,Lotta Hansson

European journal of haematology（2023）

引用 0|浏览1

暂无评分

摘要

Our real-world results suggest that idelalisib is an effective and relatively safe treatment for patients with advanced-stage CLL when no other therapies exist. Alternative dosing regimens and new PI3K inhibitors should be explored, particularly in patients who are double-refractory to inhibitors of BTK and Bcl-2.

查看译文

关键词

CLL,PI3Kδ inhibitor,idelalisib,real-world

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要